Biomimetic functionalization with leukocyte membranes imparts cell like functions to synthetic particles
By A. Parodi, N. Quattrocchi, Anne L. van de Ven, C. Chiappini, M. Evangelopoulos, Jonathan O. Martinez, Brandon S. Brown, Sm Z. Khaled, Iman K. Yazdi, M. Enzo and 3 more. Nature Nanotechnology, 2012
1,027 citations recorded by the source corpus.
The therapeutic efficacy of systemic drug delivery vehicles depends on their ability to evade the immune system, cross the biological barriers of the body and localize at target tissues. Leukocytes possess all of these functions and exert their targeting ability through cellular membrane interactions. Here we show that NanoPorous Silicon particles (NPS) can successfully perform all these actions when coated with cellular membranes purified from white blood cells. These hybrid particles called LeukoLike Vectors (LLV) were able to: prevent rapid clearance of phagocytic cells of the immune system; communicate with endothelial cells through receptor-ligand interaction; transport and release a payload across an inflamed reconstructed endothelium. Furthermore, LLV retained their functions when injected in vivo, showing enhanced circulation time and improved accumulation in the tumour.
Subfields: Biomaterials, Biomedical Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/1e8ccc25c6107e078960fbe01d0d6c0cba571f93
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Yunxiang Zhou
- Yihan Yao
- Lihong Liu
- Yali Wang
- Yajun Wang
- T. Gong
- Shijie Wu
- Yanyan Xu
Citations in the corpus
- Nanomedicine in cancer therapy (2023, background): “Further analyses revealed that LLV recognition of and binding to inflamed endothelium was mediated mainly by lymphocyte function-associated antigen 1 (LFA-1) expressed on the membrane of leukocytes, and intercellular adhesion molecule-1 (ICAM-1) found on the surface of endothelial cells during infla”
- Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance (2020, background): “…efflux transporters NP itself (Murakami et al., 2011) Inhibit efflux transporters COX-2 inhibitors (Zhang S. et al., 2019) P-gp-targeted siRNA (Patil et al., 2010; Navarro et al., 2012) miRNA-495 (He et al., 2019) Apoptosis Inhibit anti-apoptosis pathway Bcl-2-targeted siRNA (Wang et al.,…”